These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 28271446)

  • 1. In vitro-engineered non-antibody protein therapeutics.
    Simeon R; Chen Z
    Protein Cell; 2018 Jan; 9(1):3-14. PubMed ID: 28271446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of new protein scaffold-based agents for treatment of cancer.
    Weidle UH; Auer J; Brinkmann U; Georges G; Tiefenthaler G
    Cancer Genomics Proteomics; 2013; 10(4):155-68. PubMed ID: 23893924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties.
    Skerra A
    J Biotechnol; 2001 Jun; 74(4):257-75. PubMed ID: 11526907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics.
    Boersma YL
    Methods Mol Biol; 2018; 1798():307-327. PubMed ID: 29868969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticalins as an alternative to antibody technology.
    Schlehuber S; Skerra A
    Expert Opin Biol Ther; 2005 Nov; 5(11):1453-62. PubMed ID: 16255649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adnectins: engineered target-binding protein therapeutics.
    Lipovsek D
    Protein Eng Des Sel; 2011 Jan; 24(1-2):3-9. PubMed ID: 21068165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy.
    Plückthun A
    Annu Rev Pharmacol Toxicol; 2015; 55():489-511. PubMed ID: 25562645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designed ankyrin repeat proteins as scaffolds for multivalent recognition.
    Hollenbeck JJ; Danner DJ; Landgren RM; Rainbolt TK; Roberts DS
    Biomacromolecules; 2012 Jul; 13(7):1996-2002. PubMed ID: 22681396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
    Weisser NE; Hall JC
    Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered Protein Scaffolds as Next-Generation Therapeutics.
    Gebauer M; Skerra A
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():391-415. PubMed ID: 31914898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.
    Li D; Gong R; Zheng J; Chen X; Dimitrov DS; Zhao Q
    Biochem Biophys Res Commun; 2017 Apr; 485(2):446-453. PubMed ID: 28202413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module.
    Kramer MA; Wetzel SK; Plückthun A; Mittl PR; Grütter MG
    J Mol Biol; 2010 Dec; 404(3):381-91. PubMed ID: 20851127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-Immunoglobulin Synthetic Binding Proteins for Oncology.
    David TI; Pestov NB; Korneenko TV; Barlev NA
    Biochemistry (Mosc); 2023 Sep; 88(9):1232-1247. PubMed ID: 37770391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.